1Jacobi AM,Odendahl M,Reiter K,Brans A,Burmester GR,Radbrach A,et al.Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.Arthritis Rheum 2003;48:1332-1342.
2Odendahl M,Jacobi A,Hansen A,Feist E,Hiepe E Burmester GR,et al.Disturbed peripheral B-cell homeostasis in systemic lupus erythematosus.J Immunol 2000;165:5970-5979.
3Lindenau S,Scholze S,Odendahl M,Dorner T,Radbruch A,Burmester GR,et al.Aberrant activation of B-cells in patients with rheumatoid arthritis.Ann N Y Acad Sci 2003;987:246-248.
4Toussirot E,Lafforgue E Boucrant J,Despieds E Schiano A,Bernard D,et ai.Serum levels of interleukin 1-beta,tumor necrosis factor-alpha soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies.Rheumatol Int 1994;13:175-180.
5Gorman JD,Sack KE,Davis JC Jr.Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.N Engl J Meal 2002;346:1349-1356.
6McLeod C,Bagust A,Boland A,Dagenais P,Dickson R,Dundar Y,et al.Adalimumab,etanercept and infliximab for the treatment of ankylosing spondylitis:a systematic review and economic evaluation.Health Technol Assess 2007;11:1-158,iii-iv.
7Davis JC Jr,van tier Heijde DM,Braun J,Dougados M,Clegg DO,Kivitz AJ,et al.Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.Ann Rheum Dis 2008;67:346-352.
8Calin A,Dijkmans BA,Emery P,Hakala M,Kalden J,Leirisalo-Repo M,et al.Outcomes of a multicenter randomized clinical trial of etanercept to treat ankylosing spondylitis.Ann Rheum Dis 2004;63:1594-1600.
9Van der Linden S J,Valkenburg HA,Cats A.Evaluation of diagnostic criteria for ankylosing spondylitis:a proposal for modification of the New York criteria.Arthritis Rheum 1984;27:361-368.
10Arnett FC,Edworthy SM,Bloch DA,McShane DJ,Fries IF,Cooper NS,et al.The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis.Arthritis Rheum 1988;31:315-324.
